Philip A Routledge

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2284543/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Important Drug-Drug Interactions in the Elderly. Drugs and Aging, 1998, 12, 485-494.	2.7	137
2	Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0174730.	2.5	120
3	The European Herbal Medicines Directive. Drug Safety, 2008, 31, 416-418.	3.2	29
4	Abolition of Prescription Copayments in Wales: An Observational Study on Dispensing Rates. Value in Health, 2010, 13, 675-680.	0.3	14
5	Safe prescribing: a titanic challenge. British Journal of Clinical Pharmacology, 2012, 74, 676-684.	2.4	13
6	New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes. Pharmacoeconomics, 2018, 36, 613-624.	3.3	12
7	An evaluation of rational prescribing in hospital outpatient practice in Sierra Leone and assessment of affordability of a prescription as an outcome. Pan African Medical Journal, 2018, 31, 174.	0.8	12
8	A national inâ€patient prescription chart: the experience in Wales 2004–2012. British Journal of Clinical Pharmacology, 2012, 74, 561-565.	2.4	11
9	Estimated Versus Observed Expenditure Associated with Medicines Recommended by the All Wales Medicines Strategy Group. PharmacoEconomics - Open, 2019, 3, 343-350.	1.8	8
10	Morphine in Children with Cancer. Journal of Pain and Palliative Care Pharmacotherapy, 2007, 21, 5-12.	0.8	6
11	Therapeutic Drug Monitoring (TDM). , 2013, , 945-962.		4
12	Public awareness in Wales of the UK Yellow Card scheme for reporting suspected adverse drug reactions. British Journal of Clinical Pharmacology, 2021, 87, 3344-3348.	2.4	4
13	An agenda for UK clinical pharmacology: Developing and delivering clinical pharmacology in the UK National Health Service. British Journal of Clinical Pharmacology, 2012, 73, 884-887.	2.4	3
14	Impact of the phased abolition of co-payments on the utilisation of selected prescription medicines in Wales. Health Economics (United Kingdom), 2018, 27, 236-243.	1.7	2
15	Medicines identified as low priority for funding: a Welsh perspective. Journal of the Royal Society of Medicine, 2019, 112, 268-268.	2.0	2
16	The All Wales Medicines Strategy Group: 18 years' experience of a national medicines optimisation committee. British Journal of Clinical Pharmacology, 2021, 87, 3961-3970.	2.4	2
17	Adverse drug reactions to herbal medicines. Adverse Drug Reaction Bulletin, 2021, 331, 1283-1286.	O.5	2
18	Changes in suspected adverse drug reaction reporting via the yellow card scheme in Wales following the introduction of a National Reporting Indicator. British Journal of Clinical Pharmacology, 2022, , .	2.4	2

#	Article	IF	CITATIONS
19	Combination therapy of diseases: general concepts. , 2005, , 3-15.		1
20	Medication safety – pharmacy's contribution: call for papers. International Journal of Pharmacy Practice, 2019, 27, 477-478.	0.6	0
21	How do pharmacists contribute to global medication safety?. International Journal of Pharmacy Practice, 2020, 28, 549-551.	0.6	0